WILMER MOUNGER: Open Payments
NPI 1396391942 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$756 in 33 payments from 14 companies in 2025. Trend: 2023 $38 · 2024 $263 · 2025 $756
Food & beverage: $756
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $151 |
| Incyte Corporation | 5 | $111 |
| Merck Sharp & Dohme LLC | 4 | $95 |
| Eisai Inc. | 4 | $82 |
| Genmab U.S., Inc. | 2 | $58 |
| Genentech USA, Inc. | 2 | $49 |
| Regeneron Healthcare Solutions, Inc. | 2 | $39 |
| Rigel Pharmaceuticals, Inc. | 2 | $32 |
| Pharmacosmos Therapeutics Inc. | 1 | $30 |
| Janssen Biotech, Inc. | 1 | $27 |
Products named: KEYTRUDA, JAKAFI, Lenvima, ENHERTU, Epkinly, CARVYKTI, LIBTAYO, TAVALISSE.
Industry payments across TX — which companies pay providers there.
